Cambridge Healthtech Institute’s Third Annual

Cancer Biotherapeutics

Immune Targeting, ADCs, Novel Engineering, and Combination Approaches

5-6 November 2015

Research for this year’s Cancer Biotherapeutics track revealed rapid developments and huge enthusiasm for immunotherapy approaches for cancer. This conference presents the FDA-approved BiTe antibody and additional developments with engaging T cells and NK cells. There is huge excitement around the mechanism of action and therapeutic potential of check point inhibitors which are providing exciting results in the clinic. Equally fascinating is CAR (Chimeric-Antigen Receptor) T cell therapy in which the patients’ cells are engineered to treat their own cancers which is also be covered in this conference. Developments with enhancing potency, stability, and half-life and with manufacturing are presented, as well as synergistic effects with ADCs.

Advances with ADCs include a platform for low-expression targets, developability assessment and the pharmacological benefits of site-specific conjugation, and also ADC/bispecific combination approaches.

This track complements the previous tracks in the Antibody Engineering Stream which include many presentations on cancer biotherapeutics, in particular bispecifics.

Preliminary Agenda


Cancer Therapy by T Cell-Engaging Antibody Constructs

Tobias Raum, Ph.D., Scientific Director, Lead Generation, AMGEN Research (Munich) GmbH

Bispecific Antibodies for Redirecting T Cell Killing: Ag and Ab Factors Affecting the Killing Potency

Diego Ellerman, Ph.D., Senior Research Associate, Protein Chemistry, Genentech, Inc.


A Novel T Cell-Engaging Bispecific Format with Full-Length Antibody Properties - Applications in Cancer Immunotherapy

Seung Y. Chu, Ph.D., Associate Director, Cell Biology, Xencor, Inc.

Immtacs: Bi-Specific TCR-Based Reagents for Targeted Cancer Immunotherapy

Joseph Dukes, Ph.D., Head, Preclinical Biology, Cell Biology, Immunocore Ltd.


Advances with Chimeric Antigen Receptor Therapy

Jos Melenhorst, Ph.D., Director, Product Development & Correlative Sciences Labs, University of Pennsylvania


Innovations in Cancer Biotherapeutics: Immune Checkpoints Antagonist, Agonists and Combinations

Rakesh Dixit, Ph.D., Vice President, Safety Assessment, Medimmune (A member of AstraZeneca)

Understanding How Isotype Determines the Mechanism of Action of Immunomodulatory Antibodies in the Treatment of Cancer

Stephen Beers, Ph.D., Associate Professor, Cancer Sciences Unit, Faculty of Medicine, University of Southampton

Combinations of Check-Point Inhibitors with the First-in-Class Therapeutic NK-Cell Binding TandAb AFM13 (CD30/CD16A)

Martin Treder, Ph.D., CSO, Affimed


T-DM1 Reinstates Anti-Tumor Immunity in HER2-Positive Breast Cancer: Synergies with α-CTLA-4 and α-PD-1

Philipp Müller, Ph.D., Project Leader, Biomedicine, University Hospital of Basel


Targeting of Solid Tumors with Bi-Specifics and Bi-Specific ADCs to Induce Novel Biologics and Drug-Like Properties

David Poon, Ph.D., Senior Director, External Research & Development and Alliances, Zymeworks, Inc.


Improving Potency and Stability of Antibody Drug Conjugates

Pavel Strop, Ph.D., Associate Research Fellow, Protein Engineering, Rinat-Pfizer

Advances and Applications of the Fleximer Platform Approach to ADCs

Tim Lowinger, Ph.D., CEO, Mersana Therapeutics

Developability Assessment of ADCs – A Case Study

Lars Linden, Ph.D., Head, Protein Biochemistry, Global Biologics, Cell and Protein Sciences, Bayer Healthcare

For more details on the conference, please contact: 

Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
Tel: +44 7791 866489

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452